Literature DB >> 3323258

Chloroquine elimination in humans: effect of low-dose cimetidine.

E I Ette1, E A Brown-Awala, E E Essien.   

Abstract

A controlled study was carried out in ten healthy, male volunteers (randomly distributed into control and test groups of five subjects each) to determine the effect of low-dose cimetidine on chloroquine elimination. The control group subjects received two tablets of chloroquine sulfate (300-mg base) only, while the test group subjects took 400-mg cimetidine at bedtime for four days prior to chloroquine (two tablets of chloroquine sulfate) administration and throughout the duration of the study. Blood samples, 5 mL, were collected periodically after chloroquine administration. The samples were assayed for chloroquine and monodesethylchloroquine using a combination of thin-layer chromatography and spectrophotometry. Wilcoxon's test for unpaired data at P less than .05 was used to determine if there was any significant difference in the elimination of chloroquine in the test group when compared with the control group. The apparent oral clearance rate of chloroquine was reduced from 0.49 +/- 0.04 L/d/kg in the control group to 0.23 +/- 0.02 L/d/kg in the test group, and the elimination half-life was prolonged from 3.11 days in the control group to 4.62 days in the test group. There was a 47.04% reduction in the AUC0-7d of monodesethylchloroquine, the major metabolite of chloroquine, in the test group when compared with the control group. The apparent volume of distribution at steady state was increased from 0.46 +/- 0.07 L/kg in the control group to 0.72 +/- 0.10 L/kg in the test group. All these changes were statistically significant. The conclusion is that cimetidine impairs the elimination of chloroquine in healthy subjects.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3323258     DOI: 10.1002/j.1552-4604.1987.tb03002.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  13 in total

1.  Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine.

Authors:  Fabian Müller; Jörg König; Hartmut Glaeser; Ingrid Schmidt; Oliver Zolk; Martin F Fromm; Renke Maas
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

2.  Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria.

Authors:  Jens Rengelshausen; Jürgen Burhenne; Margit Fröhlich; Yorki Tayrouz; Shio Kumar Singh; Klaus-Dieter Riedel; Olaf Müller; Torsten Hoppe-Tichy; Walter E Haefeli; Gerd Mikus; Ingeborg Walter-Sack
Journal:  Eur J Clin Pharmacol       Date:  2004-10-13       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 5.  Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates.

Authors:  Radouil Tzekov
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

6.  Chronic use of chloroquine disrupts the urine concentration mechanism by lowering cAMP levels in the inner medulla.

Authors:  Tobias N von Bergen; Mitsi A Blount
Journal:  Am J Physiol Renal Physiol       Date:  2012-07-11

Review 7.  Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy.

Authors:  R Matthew Chico; Daniel Chandramohan
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-07-07       Impact factor: 4.481

Review 8.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

Review 9.  Clinically important drug interactions with disease-modifying antirheumatic drugs.

Authors:  C J Haagsma
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 4.271

Review 10.  FIRST REPORTS OF CLINICAL PHARMACOKINETICS IN NIGERIA.

Authors:  O S Michael
Journal:  Ann Ib Postgrad Med       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.